The Relative Strength (RS) Rating for Harmony Biosciences entered a higher percentile Friday, as it got a lift from 68 to 71.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves. See if Harmony Biosciences can continue to show renewed price strength and clear that threshold.
Harmony Biosciences is working on a consolidation with a 41.61 buy point. See if the stock can clear the breakout price in volume at least 40% above average.
The company posted 17% earnings growth in its most recent report. Sales rose 19%. The next quarterly results are expected on or around Aug. 12.
Harmony Biosciences earns the No. 6 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
